Tropical Storm Alma made landfall on Thursday on Costa Rica’s Pacific Coast and blew through to Nicaragua, where 35,000 people were being evacuated.
The Miami-based US National Hurricane Centre (NHC) said that a tropical storm warning was in effect for the Pacific Coast of Central America, including Nicaragua, Honduras and El Salvador.
The eye of the storm was 85km west-northwest of Managua and about 280km east-south-east of San Salvador. According to the NHC report, it was moving northward at 15km an hour and was expected to turn northwest by yesterday.
Maximum sustained winds were near 100kph, with higher gusts.
The storm was expected to weaken overnight as it continued to move inland.
Nicaraguan civil defense boss Mario Perez-Cassar said that some 3,000 personnel had been deployed in low-lying areas, alongside military and police officers and Red Cross workers.
He said that 225 “critical points” were identified in the western provinces of Leon and Chinandega, with 23 municipalities at risk of suffering severe flooding, mudslides and flashfloods.
“We have a few hours to take away as many people as possible,” Perez-Cassar said.
He said that 25,000 people were to be evacuated first, with another 10,000 to follow.
Schools were closed on Thursday and yesterday in the provinces of Leon and Chinandega, in the southern provinces of Carazo and Rivas and in Managua.
Alma took authorities by surprise, having formed at an unusual location and time of year and surging in strength from a tropical depression to a powerful storm system within a few hours.
It dumped heavy rains across Central America.
Along Costa Rica’s Pacific coast, particularly in Parrita and Quepos, 250 people suffered damage to their property and had to move into emergency shelters.
The Costa Rican soccer championship final between archrivals Alajuela and Saprissa was postponed on Thursday.
The COVID-19 variant discovered in South Africa can “break through” Pfizer-BioNTech’s COVID-19 vaccine to some extent, a real-world data study released on Saturday found, although its prevalence in the country is low and the research has not been peer reviewed. The study in Israel compared almost 400 people who had tested positive for COVID-19, 14 days or more after they received one or two doses of the vaccine, against the same number of unvaccinated people with the disease. It matched age and gender, among other characteristics. The South African variant, B.1.351, was found to make up about 1 percent of all the COVID-19
RARE ADMISSION: A top Chinese expert was the first to publicly address the efficacy of the nation’s vaccines as it aims to inoculate 40 percent of its population by June China is considering mixing different COVID-19 vaccines to improve the relatively low efficacy of its existing options, a top health expert told a conference in Chengdu on Saturday. Authorities have to “consider ways to solve the issue that efficacy rates of existing vaccines are not high,” Chinese media outlet The Paper reported, citing Chinese Center for Disease Control and Prevention Director Gao Fu (高福). His comments mark the first time a top Chinese expert has publicly alluded to the relatively low efficacy of the country’s vaccines, as China forges ahead in its mass vaccination campaign and exports its jabs around the world. China
The Australian government yesterday said that it had decided against buying the single-dose Johnson & Johnson (J&J) COVID-19 vaccine and identified a second case of a rare blood clot likely linked to the AstraZeneca shot. The Australian government had been in talks with the New Jersey-based pharmaceutical giant, which had asked the Australian Therapeutic Goods Administration for provisional registration. However, Australian Minister of Health Greg Hunt ruled out a J&J contract, because its vaccine was similar to the AstraZeneca product, which Australia had already contracted for 53.8 million doses. Hunt said the government was following the advice of Australia’s scientific and technical advisory
The Indonesian government has said it is satisfied with the effectiveness of the Chinese COVID-19 vaccine it has been using, after China’s top disease control official said that current vaccines offer low protection against the novel coronavirus. Siti Nadia Tarmizi, a spokesperson for Indonesia’s COVID-19 vaccine program, on Monday said the WHO had found that the Chinese vaccines had met requirements by being more than 50 percent effective. Clinical trials in Indonesia for the vaccine from Chinese drugmaker Sinovac showed that it was 65 percent effective, she said. “It means ... the ability to form antibodies in our bodies is still very